Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome:Focusing on inflammation and molecular mechanisms  

作　　者：Mohammad Yasin Zamanian Hamidreza Zafari Maria K.Osminina Alla A.Skakodub Raed Fanoukh Aboqader Al-Aouadi Maryam Golmohammadi Nikta Nikbakht Iman Fatemi 

机构地区：[1]Department of Physiology,School of Medicine,Hamadan University of Medical Sciences,Hamadan,Iran [2]Department of Pharmacology and Toxicology,School of Pharmacy,Hamadan University of Medical Sciences,Hamadan,Iran [3]Department of Orthopedic Surgery,Joint Reconstruction Research Center,Imam Khomeini Hospital Complex,School of Medicine,Tehran University of Medical Sciences,Tehran,Iran [4]Pediatric department,I.M.Sechenov First Moscow State Medical University of the Ministry of Health of Russia(Sechenov University),Moscow,Russian Federation [5]Department of Pediatric Preventive Dentistry E.V.Borovsky,I.M.Sechenov First Moscow State Medical University of the Ministry of Health of Russia(Sechenov University),Moscow,Russian Federation [6]Department of Medicine,College of Medicine,Al-Ayen Iraqi University,Thi-Qar,Iraq [7]School of Medicine,Shahid Beheshti University of Medical Sciences,Tehran,Iran [8]Department of Physical Medicine and Rehabilitation,School of Pharmacy,Hamadan University of Medical Sciences,Hamadan,Iran [9]Research Center of Tropical and Infectious Diseases,Kerman University of Medical Sciences,Kerman,Iran

出　　处：《Animal Models and Experimental Medicine》2025年第1期5-19,共15页动物模型与实验医学(英文)

摘　　要：Rheumatoid arthritis(RA)is a chronic autoimmune disease that affects approxi-mately 0.46%of the global population.Conventional therapeutics for RA,including disease-modifying antirheumatic drugs(DMARDs),nonsteroidal anti-inflammatory drugs(NSAIDs),and corticosteroids,frequently result in unintended adverse effects.Dexamethasone(DEX)is a potent glucocorticoid used to treat RA due to its anti-inflammatory and immunosuppressive properties.Liposomal delivery of DEX,particu-larly when liposomes are surface-modified with targeting ligands like peptides or sialic acid,can improve drug efficacy by enhancing its distribution to inflamed joints and minimizing toxicity.This study investigates the potential of liposomal drug delivery systems to enhance the efficacy and targeting of DEX in the treatment of RA.Results from various studies demonstrate that liposomal DEX significantly inhibits arthritis progression in animal models,reduces joint inflammation and damage,and alleviates cartilage destruction compared to free DEX.The liposomal formulation also shows better hemocompatibility,fewer adverse effects on body weight and immune organ index,and a longer circulation time with higher bioavailability.The anti-inflammatory mechanism is associated with the downregulation of pro-inflammatory cytokines like tumor necrosis factor-α(TNF-α)and B-cell-activating factor(BAFF),which are key players in the pathogenesis of RA.Additionally,liposomal DEX can induce the expres-sion of anti-inflammatory cytokines like interleukin-10(IL-10),which has significant anti-inflammatory and immunoregulatory properties.The findings suggest that lipo-somal DEX represents a promising candidate for effective and safe RA therapy,with the potential to improve the management of this debilitating disease by providing targeted delivery and sustained release of the drug.

关 键 词：DEXAMETHASONE INFLAMMATION LIPOSOME rheumatoid arthritis TNF-α 

分 类 号：R593.22[医药卫生—内科学]